

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Feige et al.

Serial No.: 10/666,696

Group Art Unit No.: 1642

Filed: September 19, 2003

Examiner: Teresa D. Wesendorf

For: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

Docket No.: A-527H

INFORMATION DISCLOSURE STATEMENT
BEFORE
MAILING DATE OF EITHER A FINAL ACTION OR NOTICE
OF ALLOWANCE (37 CFR 1.97(c))

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,
 whichever occurs first.

STATEMENT OR FEE

Accompanying this transmittal is:

A ☐ a statement as specified in 37 CFR 1.97(e):

STATEMENT


EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number: EL 732696330 US

Date of Deposit: December 3, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sherry L. St. Andrew
 Printed Name


 Signature

I, the person(s) signing below state:

- ☐ that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(1).

OR

- ☐ that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(2).

OR

- B. ☒ the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under § 1.97(c). (\$180.00).


Applicants request consideration of this information and passage of the application to issue.

FEE PAYMENT

Please charge Deposit Account No. 01-0519 in the amount of \$180.00 (37 CFR 1.97(c)). An original and one copy are enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,



Timothy J. Gaur
Attorney for Applicants
Registration No.: 33,111
Phone: (805) 447-2688
Date: December 3, 2004

Please send all future correspondence to:
US Patent Operations/ [TJG]
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	A-527H	Serial No.	Not Yet Assigned
	Applicant			
	Feige et al			
	Filing Date	September 19, 2003	Group	1642

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
						YES NO
	BB1	EP 0 173 494	03/05/86	Morrison et al.		
	BB2	EP 0 325 224	07/26/89	Sledziewski et al.		
	BB3	EP 0 585 287	03/09/94	Winter et al.		
	BB4	WO 00/09560	02/24/00	PCT		
	BB5	WO 01/02440	01/11/01	PCT		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	CC1	Becker et al. (1989), "Expression of a Hybrid Immunoglobulin- T cell Receptor Protein in Transgenic Mice," <i>Cell</i> 58: 911-921.
	CC2	Bernard et al. (1980), "Nucleotide sequence of immunoglobulin heavy chain joining segments between translocated V _H and μ constant region genes," <i>Proc. Natl. Acad. Sci. USA</i> 77(6): 3630-3634.
	CC3	Boulianne et al. (1984), "Production of functional chimaeric Mousem/human antibody," <i>Nature</i> 312: 643-646.
	CC4	Chamow et al. (1996), "Immunoadhesins: principles and applications," <i>Tibtech</i> . 14:52- 60.
	CC5	Garber et al. (2001), "A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis," <i>J. Lipid Research</i> 42: 545-552.
	CC6	Gascoigne et al. (1987), "Secretion of a chimeric T-cell receptor-immunoglobulin protein," <i>Proc. Natl. Acad. Sci. USA</i> 84: 2936-2940.
	CC7	Kemp et al. (1981), "Direct Immunoassay for detecting Escherichia coli colonies that contain polypeptides encoded by cloned DNA segments," <i>Proc. Natl. Acad. Sci. USA</i> 78(7):4520-4524.
	CC8	Knapp et al. (1989), "Towards a better definition of human leucocyte surface molecules," <i>Immunology Today</i> 10(8):253-258.
	CC9	Mariuzza et al. (1989), "Secretion of a Homodimeric V _a C _K t-cell Receptor-Immunoglobulin Chimeric Protein," <i>J. Biological Chemistry</i> 264(13):7310-7316.
	CC10	Morrison (1985), "Transfectomas Provide Novel Chimeric Antibodies," <i>Science</i> 229:1202-1207.
	CC11	Morrison et al. (1984), "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci. USA</i> 81:6851-6855.
	CC12	Munro (1984), "Uses of chimaeric antibodies," <i>Nature</i> 312:597-.
	CC13	Neuberger et al. (1984), "Recombinant antibodies possessing novel effector functions," <i>Nature</i> 312:604-608.

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	A-527H	Serial No.	Not Yet Assigned
	Applicant			
	Feige et al			
	Filing Date	September 19, 2003	Group	1642

	CC14	Sharon et al. (1984), "Expression of a V _H C _K chimaeric protein in mouse myeloma cells," <i>Nature</i> 309:364- 367.
	CC15	Traunecker et al. (1986), "A novel approach for preparing anti-T cell receptor constant region antibodies," <i>Eur. J. Immunol.</i> 16: 851-853.
	CC16	Traunecker et al. (1988), "Soluble CD4 molecules neutralize human immunodeficiency virus type 1," <i>Nature</i> 331:84-86.
	CC17	Traunecker et al. (1989), "Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules," <i>Nature</i> 339: 68-70.

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	